{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:20:11Z","timestamp":1789017611325,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00259-024-06677-y","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T06:07:44Z","timestamp":1710223664000},"page":"2495-2503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["[177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study"],"prefix":"10.1007","volume":"51","author":[{"given":"Swayamjeet","family":"Satapathy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav Prasad","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Ballal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit Kumar","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4378-5584","authenticated-orcid":false,"given":"Chandrasekhar","family":"Bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"6677_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"6677_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-3-319-99286-0_7","volume":"1096","author":"A Mansinho","year":"2018","unstructured":"Mansinho A, Macedo D, Fernandes I, et al. Castration-resistant prostate Cancer: mechanisms, targets and treatment. Adv Exp Med Biol. 2018;1096:117\u201333.","journal-title":"Adv Exp Med Biol"},{"key":"6677_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate Cancer. Part II-2020 update: treatment of relapsing and metastatic prostate Cancer. Eur Urol. 2021;79:263\u201382.","journal-title":"Eur Urol"},{"key":"6677_CR4","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312.","journal-title":"N Engl J Med"},{"key":"6677_CR5","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995\u20132005.","journal-title":"N Engl J Med"},{"key":"6677_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152\u201360.","journal-title":"Lancet Oncol"},{"key":"6677_CR7","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"key":"6677_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","volume":"71","author":"TM Beer","year":"2017","unstructured":"Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in men with Chemotherapy-na\u00efve metastatic castration-resistant prostate Cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71:151\u20134.","journal-title":"Eur Urol"},{"key":"6677_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.eururo.2016.08.037","volume":"71","author":"J Mateo","year":"2017","unstructured":"Mateo J, Boysen G, Barbieri CE, et al. DNA repair in prostate Cancer: Biology and Clinical implications. Eur Urol. 2017;71:417\u201325.","journal-title":"Eur Urol"},{"key":"6677_CR10","doi-asserted-by":"publisher","first-page":"564601","DOI":"10.3389\/fcell.2020.564601","volume":"8","author":"M Rose","year":"2020","unstructured":"Rose M, Burgess JT, O\u2019Byrne K, et al. PARP inhibitors: clinical relevance, mechanisms of Action and Tumor Resistance. Front Cell Dev Biol. 2020;8:564601.","journal-title":"Front Cell Dev Biol"},{"key":"6677_CR11","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.3390\/cancers15061849","volume":"15","author":"S Tisseverasinghe","year":"2023","unstructured":"Tisseverasinghe S, Bahoric B, Anidjar M, et al. Advances in PARP inhibitors for prostate Cancer. Cancers (Basel). 2023;15:1849.","journal-title":"Cancers (Basel)"},{"key":"6677_CR12","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","volume":"41","author":"KN Chi","year":"2023","unstructured":"Chi KN, Rathkopf D, Smith MR, et al. Niraparib and Abiraterone acetate for metastatic castration-resistant prostate Cancer. J Clin Oncol. 2023;41:3339\u201351.","journal-title":"J Clin Oncol"},{"key":"6677_CR13","doi-asserted-by":"publisher","first-page":"EVIDoa2200043","DOI":"10.1056\/EVIDoa2200043","volume":"1","author":"NW Clarke","year":"2022","unstructured":"Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 2022;1:EVIDoa2200043.","journal-title":"NEJM Evid"},{"key":"6677_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","volume":"402","author":"N Agarwal","year":"2023","unstructured":"Agarwal N, Azad AA, Carles J, et al. Talazoparib plus Enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402:291\u2013303.","journal-title":"Lancet"},{"key":"6677_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jaccao.2019.09.005","volume":"1","author":"A Tanaka","year":"2019","unstructured":"Tanaka A, Node K. The Emerging and Promising Role of Care for Cardiometabolic syndrome in prostate Cancer. JACC CardioOncol. 2019;1:307\u20139.","journal-title":"JACC CardioOncol"},{"key":"6677_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2214\/AJR.18.20845","volume":"213","author":"MP Yadav","year":"2019","unstructured":"Yadav MP, Ballal S, Sahoo RK, et al. Radioligand Therapy with 177Lu-PSMA for metastatic castration-resistant prostate Cancer: a systematic review and Meta-analysis. AJR Am J Roentgenol. 2019;213:275\u201385.","journal-title":"AJR Am J Roentgenol"},{"key":"6677_CR17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804.","journal-title":"Lancet"},{"key":"6677_CR18","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate Cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"6677_CR19","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1007\/s00259-021-05618-3","volume":"49","author":"S Satapathy","year":"2022","unstructured":"Satapathy S, Mittal BR, Sood A, et al. 177Lu-PSMA-617 versus docetaxel in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial. Eur J Nucl Med Mol Imaging. 2022;49:1754\u201364.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6677_CR20","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.2967\/jnumed.123.266141","volume":"64","author":"S Satapathy","year":"2023","unstructured":"Satapathy S, Mittal BR, Sood A, et al. [177Lu]Lu-PSMA-617 Versus Docetaxel in Chemotherapy-Na\u00efve metastatic castration-resistant prostate Cancer: final survival analysis of a phase 2 Randomized, Controlled Trial. J Nucl Med. 2023;64:1726\u20139.","journal-title":"J Nucl Med"},{"key":"6677_CR21","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/pros.24325","volume":"82","author":"MS Sadaghiani","year":"2022","unstructured":"Sadaghiani MS, Sheikhbahaei S, Werner RA, et al. 177 Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: an updated systematic review and meta-analysis. Prostate. 2022;82:826\u201335.","journal-title":"Prostate"},{"key":"6677_CR22","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, et al. Trial Design and objectives for castration-resistant prostate Cancer: updated recommendations from the prostate Cancer clinical trials Working Group 3. J Clin Oncol. 2016;34:1402\u201318.","journal-title":"J Clin Oncol"},{"key":"6677_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"issue":"Suppl 2","key":"6677_CR24","doi-asserted-by":"publisher","first-page":"S1324","DOI":"10.1016\/j.annonc.2023.10.085","volume":"34","author":"O Sartor","year":"2023","unstructured":"Sartor O, Castellano Gauna DE, Herrmann K, et al. LBA13 phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore). Ann Oncol. 2023;34(Suppl 2):S1324\u20135.","journal-title":"Ann Oncol"},{"key":"6677_CR25","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.eururo.2021.06.012","volume":"80","author":"S Satapathy","year":"2021","unstructured":"Satapathy S, Das N, Sood A, et al. Short-course 177Lu-PSMA-617 Radioligand Therapy in High-volume metastatic hormone-sensitive prostate Cancer: time to take the Leap? Eur Urol. 2021;80:390\u20132.","journal-title":"Eur Urol"},{"key":"6677_CR26","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1158\/1078-0432.CCR-20-4298","volume":"27","author":"BM Priv\u00e9","year":"2021","unstructured":"Priv\u00e9 BM, Peters SMB, Muselaers CHJ, et al. Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate Cancer: a prospective pilot study. Clin Cancer Res. 2021;27:3595\u2013601.","journal-title":"Clin Cancer Res"},{"key":"6677_CR27","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","volume":"38","author":"ND Shore","year":"2021","unstructured":"Shore ND, Lalibert\u00e9 F, Ionescu-Ittu R, et al. Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate Cancer in the US prior to PARP inhibitors. Adv Ther. 2021;38:4520\u201340.","journal-title":"Adv Ther"},{"key":"6677_CR28","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1177\/03008916221079662","volume":"109","author":"L Galli","year":"2023","unstructured":"Galli L, Chiuri VE, Di Lorenzo G, et al. First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the prostate Cancer Registry. Tumori. 2023;109:224\u201332.","journal-title":"Tumori"},{"key":"6677_CR29","doi-asserted-by":"publisher","first-page":"e1921","DOI":"10.1016\/j.urolonc.2022.01.009","volume":"40","author":"B Shayegan","year":"2022","unstructured":"Shayegan B, Wallis CJD, Malone S, et al. Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada. Urol Oncol. 2022;40:e1921\u20139.","journal-title":"Urol Oncol"},{"key":"6677_CR30","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/bco2.129","volume":"3","author":"A Anton","year":"2021","unstructured":"Anton A, Pillai S, Semira MC, et al. Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer. BJUI Compass. 2021;3:205\u201313.","journal-title":"BJUI Compass"},{"key":"6677_CR31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s11523-020-00720-2","volume":"15","author":"S Chowdhury","year":"2020","unstructured":"Chowdhury S, Bjartell A, Lumen N, et al. Real-world outcomes in First-Line treatment of metastatic castration-resistant prostate Cancer: the prostate Cancer Registry. Target Oncol. 2020;15:301\u201315.","journal-title":"Target Oncol"},{"key":"6677_CR32","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s11523-021-00807-4","volume":"16","author":"A Bjartell","year":"2021","unstructured":"Bjartell A, Lumen N, Maroto P, et al. Real-world safety and efficacy outcomes with abiraterone acetate plus prednisone or prednisolone as the First- or second-line treatment for metastatic castration-resistant prostate Cancer: data from the prostate Cancer Registry. Target Oncol. 2021;16:357\u201367.","journal-title":"Target Oncol"},{"key":"6677_CR33","doi-asserted-by":"publisher","unstructured":"Freedland SJ, Davis M, Epstein AJ et al. Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population. Prostate Cancer Prostatic Dis. 2023 Oct 2. https:\/\/doi.org\/10.1038\/s41391-023-00725-8. Epub ahead of print.","DOI":"10.1038\/s41391-023-00725-8"},{"key":"6677_CR34","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.clgc.2019.12.019","volume":"18","author":"DJ George","year":"2020","unstructured":"George DJ, Sartor O, Miller K, et al. Treatment patterns and outcomes in patients with metastatic castration-resistant prostate Cancer in a real-world clinical practice setting in the United States. Clin Genitourin Cancer. 2020;18:284\u201394.","journal-title":"Clin Genitourin Cancer"},{"key":"6677_CR35","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.2967\/jnumed.123.265414","volume":"64","author":"S Satapathy","year":"2023","unstructured":"Satapathy S, Sahoo RK, Bal C. [177Lu]Lu-PSMA-Radioligand Therapy Efficacy outcomes in Taxane-Na\u00efve Versus taxane-treated patients with metastatic castration-resistant prostate Cancer: a systematic review and metaanalysis. J Nucl Med. 2023;64:1266\u201371.","journal-title":"J Nucl Med"},{"key":"6677_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41391-021-00424-2","volume":"25","author":"BM Priv\u00e9","year":"2022","unstructured":"Priv\u00e9 BM, Slootbeek PHJ, Laarhuis BI, et al. Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2022;25:71\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"6677_CR37","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/pros.24450","volume":"83","author":"S Satapathy","year":"2023","unstructured":"Satapathy S, Das CK, Aggarwal P, et al. Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: a single-center experience. Prostate. 2023;83:169\u201378.","journal-title":"Prostate"},{"key":"6677_CR38","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1097\/RLU.0000000000003307","volume":"45","author":"S Satapathy","year":"2020","unstructured":"Satapathy S, Mittal BR, Sood A. Visceral metastases as predictors of response and survival outcomes in patients of castration-resistant prostate Cancer treated with 177Lu-Labeled prostate-specific membrane Antigen Radioligand Therapy: a systematic review and Meta-analysis. Clin Nucl Med. 2020;45:935\u201342.","journal-title":"Clin Nucl Med"},{"key":"6677_CR39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2022.7070","volume":"21","author":"D Mehrens","year":"2023","unstructured":"Mehrens D, Kramer KKM, Unterrainer LM, et al. Cost-effectiveness analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-resistant prostate Cancer. J Natl Compr Canc Netw. 2023;21:43\u2013e502.","journal-title":"J Natl Compr Canc Netw"},{"key":"6677_CR40","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.6004\/jnccn.2014.0139","volume":"12","author":"CL Gong","year":"2014","unstructured":"Gong CL, Hay JW. Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer. J Natl Compr Canc Netw. 2014;12:1417\u201325.","journal-title":"J Natl Compr Canc Netw"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06677-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06677-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06677-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T06:06:05Z","timestamp":1718345165000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06677-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["6677"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06677-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]},"assertion":[{"value":"23 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institute Ethics Committee, All India Institute of Medical Sciences, New Delhi (Ref. No. IESC\/T-229\/05.05.2015, RT-46\/2015).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}